Glyxambi Injury Lawyers
Have you or a loved one suffered an injury due to taking the diabetes medication Glyxambi? If so you may be entitled to benefits as well as monetary compensation. Speaking with, and ultimately retaining, a skilled Glyxambi injury attorney is a wise move.
Please contact our Glyxambi injury lawyers here for a free consultation. They handle Glyxambi cases, which are mass tort claims, on a contingency fee basis which means they charge no legal fees of any kind unless they win for you.
What Is Glyxambi?
Glyxambi is a Type 2 diabetes medication manufactured by Boehringer Ingelheim and Eli Lilly and Company. It consists of a combination of two drugs: empagliflozin, sold under the brand name of Jardiance, and linagliptin, sold under the brand name Tradjenta. It was approved in early 2015 along with a new class of diabetic drugs. Empagliflozin works by increasing the removal of sugar in the kidneys. Linagliptin works by increasing levels of natural substances known as incretins. Incretins control blood sugar by increasing the release of insulin and decreasing the amount of sugar the liver creates.
In May 2015, the Food and Drug Administration (FDA) issued a drug safety communication indicating its investigation of users suffering from ketoacidosis after taking Glyxambi. Diabetic Ketoacidosis (DKA) is a condition in which an accumulation of high levels of acid build up in the blood. In December 2015, the FDA urged a stronger Glyxambi warning be required to inform patients to discontinue the use of the drug and seek medical assistance if they experienced any of the following conditions:
- Shortness of breath
- Nausea or vomiting
- Abdominal pain
- Confusion and fatigue
The FDA warning indicated that there were over 20 instances of DKA of patients treated with SGLT2 inhibitor drugs (similar to Glyxambi ) between March 2013 to June 2014. Boehringer Ingelheim also warned consumers that linagliptin may cause additional side effects in users including dehydration, inflammation of the pancreas, kidney disorders, and acute pancreatitis.
Glyxambi side effects include the following conditions:
- Kidney disease, stones and cancer
- Bone fracture
- Urinary tract infection
- Testicular cancer
- Severe dehydration
- Fungal infections
Glyxambi has not been recalled by the FDA. Researchers are still investigating the full effects of the drug. The rate of severe medical complications to date resulting from Glyxambi is alarming. If you have suffered any of the side effects mentioned above, contact your doctor. Do not stop taking any medication without first seeking medical attention. Our Glyxambi injury lawyers can review your injury and provide you with legal guidance and advice on how to obtain compensation for your injury.
You may have a valid claim for negligence under the theory of product liability if you can prove Boehringer Ingelheim failed to provide adequate warnings to consumers and the medical community regarding the side effects of taking Glyxambi. Drug manufacturers have a duty to fully disclose dangerous side effects of their product. If a manufacturer fails to provide consumers with sufficient information regarding their drugs, it can be held liable for negligence in the event of injury.
More research is underway to better understand the side effects Glyxambi has on the kidneys and pancreas. Our law office will provide further updates as new developments arise. Contact us to find out if you may have a valid claim against Boehringer Ingelheim.
Attorneys Handling Glyxambi Lawsuits
Currently, there is no pending Multidistrict Litigation (MDL) case for Glyxambi. Our Chicago Glyxambi injury lawyers are currently interviewing patients regarding the side effects they suffered as a result of taking Glyxambi. Time is of the essence in filing a claim.
No matter what state you were injured in our team of Miami Florida Glyxambi injury lawyers and wrongful death attorneys can help as they serve all 50 states and Washington D.C. including: Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Washington D.C., West Virginia and Wisconsin.